NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
Silver Hammer Discovers High-Grade Silver Below Historical Workings at Its 100% Wholly Owned Silverton Silver Mine Property, Nevada
Silver Hammer Discovers High-Grade Silver Below Historical Workings at Its 100% Wholly Owned Silverton Silver Mine Property, Nevada
